These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28914674)

  • 1. Frequent PD-L1 Expression in Malignant Melanomas of the Vulva.
    Saleh B; Kriegsmann J; Falk S; Aulmann S
    Int J Gynecol Pathol; 2018 Sep; 37(5):477-481. PubMed ID: 28914674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
    Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
    Thangarajah F; Morgenstern B; Pahmeyer C; Schiffmann LM; Puppe J; Mallmann P; Hamacher S; Buettner R; Alidousty C; Holz B; Scheel AH; Schultheis AM
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1651-1660. PubMed ID: 30972492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
    Choschzick M; Gut A; Fink D
    Virchows Arch; 2018 Oct; 473(4):513-516. PubMed ID: 29736798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
    Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
    J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
    Koelzer VH; Gisler A; Hanhart JC; Griss J; Wagner SN; Willi N; Cathomas G; Sachs M; Kempf W; Thommen DS; Mertz KD
    Histopathology; 2018 Sep; 73(3):397-406. PubMed ID: 29660160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in malignant salivary gland tumors.
    Harada K; Ferdous T; Ueyama Y
    BMC Cancer; 2018 Feb; 18(1):156. PubMed ID: 29409471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
    Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
    Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
    Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
    Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 17. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
    Micevic G; Thakral D; McGeary M; Bosenberg MW
    Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
    Massi D; Brusa D; Merelli B; Ciano M; Audrito V; Serra S; Buonincontri R; Baroni G; Nassini R; Minocci D; Cattaneo L; Tamborini E; Carobbio A; Rulli E; Deaglio S; Mandalà M
    Ann Oncol; 2014 Dec; 25(12):2433-2442. PubMed ID: 25223485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
    Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
    Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PD-L1 expression in trophoblastic tissues and tumors.
    Lu B; Teng X; Fu G; Bao L; Tang J; Shi H; Lu W; Lu Y
    Hum Pathol; 2019 Feb; 84():202-212. PubMed ID: 30339966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.